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Abstract
Background: Autologous transplanted fat has a high resorption rate, providing a clinical challenge for the means to reduce
it. Erythropoietin (EPO) has non-hematopoietic targets, and we hypothesized that EPO may improve long-term fat graft
survival because it has both pro-angiogenic and anti-apoptotic properties. We aimed to determine the effect of EPO on the
survival of human fat tissue after its transplantation in nude mice.
Methodology/Principal Findings: Human fat tissue was injected subcutaneously into immunologically-compromised nude
mice, and the grafts were then treated with either 20 IU or 100 IU EPO. At the end of the 15-week study period, the extent
of angiogenesis, apoptosis, and histology were assessed in the fat grafts. The results were compared to vascular endothelial
growth factor (VEGF)-treated and phosphate-buffered saline (PBS)-treated fat grafts. The weight and volume of the EPO-
treated grafts were higher than those of the PBS-treated grafts, whose weights and volumes were not different from those
of the VEGF-treated grafts. EPO treatment also increased the expression of angiogenic factors and microvascular density,
and reduced inflammation and apoptosis in a dose-dependent manner in the fat grafts.
Conclusions/Significance: Our data suggest that stimulation of angiogenesis by a cluster of angiogenic factors and
decreased fat cell apoptosis account for potential mechanisms that underlie the improved long-term survival of fat
transplants following EPO treatment.
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Introduction
During angiogenesis, endothelial cells can produce proteases
such as matrix metalloproteinases (MMPs), and can increase their
ability to migrate and proliferate [1]. This process depends on the
activity of several growth factors, such as vascular endothelial
growth factor (VEGF), basic fibroblast growth factor (bFGF) and
platelet-derived growth factor (PDGF)-BB [2,3,4].
Erythropoietin (EPO), a glycoprotein hormone that stimulates
erythropoiesis, also instigates the secretion of angiogenic factors
[5,6]. Ribatti and colleagues demonstrated that EPOinduced a pro-
angiogenic phenotype in cultured endothelial cells, and stimulated
angiogenesis in vivo [7,8]. It also stimulated angiogenesis indirectly
in ischemic tissue by increasing the expression of VEGF and by
recruiting endothelial progenitor cells [9,10]. In rats, EPO
administration mobilized bone marrow-derived progenitor cells
[11] and increased the myocardial expression of VEGF [12]. Wang
et al. demonstrated that EPO can promote angiogenesis by
stimulating VEGF secretion from neural progenitor cells and
VEGF-receptor expression in cerebral endothelial cells [13].
Other non-hematopoietic effects of EPO include cytoprotection
of vascular endothelial cells [14,15] and anti-apoptotic actions in
vascular smooth muscle cells and endothelial cells [16] such as
prevention of mitochondrial release of cytochrome c, suppression
of caspase activity, and upregulation of the activity of the protein
kinase B (PKB) signaling pathway and the expression of the
antiapoptotic protein Bcl-xl [17,18].
Autologous fat transplantation is a common and ideal technique
for soft tissue augmentation and for filling soft tissue defects due to
trauma or aging [19]. Emerging evidence suggests that early and
adequate vascularization of the fat graft is essential for its take and
viability [20,21]. However, the relatively high resorption rate of the
fat graft reduces the efficacy of this technique because the volume of
vascularized grafts continues to decline as a result of increased fat
cell death after its transplantation [22]. Although angiogenic factors
[23,24], and VEGF gene therapy, have been individually used to
stimulate angiogenesis in fat grafts in order to enhance fat cell
survival and viability [21,25,26], the clinical outcome has been
disappointing, because a single angiogenic factor to stimulate
angiogenesis may be inadequate [27]. Therefore, reducing the
resorption rate of transplanted fat is a clinical challenge.
In light of all these findings, we hypothesized that treatment of
fat grafts with EPO would (a) stimulate the release of several
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apoptosis in fat grafts. Using this working hypothesis, we initiated a
study whose aims were (a) to evaluate and compare the effects of
VEGF and EPO on fat cell survival and angiogenesis in human
transplanted fat tissue, and (b) to investigate the long-term survival
of grafted fat cells after EPO treatment in immunologically-
compromised nude mice.
Materials and Methods
Isolation and preparation of human fat tissue
Fat was harvested from the thigh of a 40-year-old woman
undergoing suction-assisted lipectomy under general anesthesia. In
order to decrease bleeding during fat aspiration, and to relieve pain
after the procedure, the areas for aspiration were injected with a
local anesthesia solution containing lidocaine (0.5%) and adrenaline
(1:1,000,000) before the beginning of the procedure. The fat was
aspirated using a 14-gauge three-hole blunt cannula, and then
processed under sterile conditions for subsequent grafting into nude
mice within two hours of its collection according to previously
published protocols [28,29]. The participant gave her written
informed consent, and the study was reviewed and approved by the
institutional review board of the Rambam Health Care Campus.
Study design
Two different animal studies were conducted, and the use of
animals and all the experimental procedures were reviewed and
approved by the Technion Animal Care and Use Committee. The
first study comprised 30 seven-week-old female CD-1 nude mice
(Harlan, Jerusalem, Israel), which were housed in cages in a room
with an artificial 12-h light/dark cycle at a constant temperature
range (2462uC) and relative humidity (55610%). The mice were
acclimated for one week prior to the study, and fed a standard
chow and water ad libitum. The 30 mice were randomly divided
into three equal groups according to treatment of the aspirated
human fat after its injection. Group 1 mice were injected with 1 ml
of human fat that was treated with sterile phosphate buffer saline
(PBS) (control group). Group 2 mice were injected with 1 ml
human fat that was treated with 1000 IU/kg EPO (low-dose EPO
group). Group 3 mice were injected with 1 ml human fat that was
treated with 5000 IU/kg EPO (high-dose EPO group). The fat
was injected subcutaneously into the scalp using a 14G needle
while the animals were manually restrained. Immediately
following fat transplantation, the fat grafts were injected with
100 ml PBS (control group), or with either 20 IU EPO/100 ml PBS
(low-dose EPO group) or 100 IU EPO/100 ml PBS (high-dose
EPO group) every three days for 18 days making a total of 6 equal
injections of each treatment per fat graft. EPO was purchased as
an injection ampoule (ARANESPH, Amgen AG, Zug, Switzer-
land) which contained 150 mg/ml (18,000 IU) of EPO.
The second animal experiment used 20 seven-week-old female
CD-1 nude mice, and differed from the first experiment in that the
fat grafts were treated with PBS or VEGF (2 mg/ml) (Sigma
Aldrich, MO, USA) after its injection into the 20 mice. Briefly, 100
ml PBS or 200 ng VEGF/100 ml PBS were injected every three
days for 18 days in an identical manner to that of the PBS- or
EPO-treated mice in the first experiment. The PBS-treated mice
in the second experiment were used as a second control group.
Post-operative analgesics and antibiotics were not administered to
the mice in the two experiments.
Follow-up and data collection
The duration of the study period of each experiment was 15
weeks after fat transplantation. On the day of fat injection, 18 days
after the fat injection, and at the end of the study period, each
mouse was weighed, and a tail vein blood sample was collected for
determining the red blood cell, leukocyte, and platelet counts, the
plasma hemoglobin, VEGF, and EPO concentrations. VEGF and
EPO concentrations were determined in the plasma as well as in
the homogenates of the samples of the fat grafts using commercial
enzyme-linked immunosorbent assays (QuantikineH VEGF im-
munoassay Kit and QuantikineH IVDH Erythropoietin Kit, R&D
Systems, MN, USA) in accordance with the manufacturer’s
instructions.
After 15 weeks, all mice were humanely killed, and the fat grafts
were carefully dissected from their scalps (Figure 1C). Each fat
graft was weighed, and the volume of the fat graft was measured
using the liquid overflow method [30]. After weight and volume
determination, each fat graft was divided into two equal portions.
One portion was stored at 280uC and used to determine its EPO
concentrations, VEGF content, extent of apoptosis, and the
expression levels of its angiogenic factors, namely bFGF, insulin
growth factor-1 (IGF-1), PDGF-BB, VEGF receptor-2 (VEGFR-
2), EPO receptor (EPOR), and MMP-2, the survival factor PKB
and phosphorylated PKB, and pro-apoptotic factors, namely
caspase 3 and cytochrome c. The second portion was placed in 4%
formalin and used for histological examination and for determi-
nation of macrophage infiltration, microvascular density (MVD),
VEGFR-2 and EPOR localization.
Histology and immunohistochemistry
Histological slides of the formalin-maintained samples were
prepared, and then stained with hematoxylin and eosin using
standard procedures. Immunohistochemistry was performed using
rabbit monoclonal antibodies against tissue CD31, VEGFR-2 and
EPOR, and goat polyclonal IgG against VEGF (R&D Systems,
Minneapolis MN, USA), and CD68 (Dako, Glostrup, Denmark).
The paraffin-embedded fat graft sections were incubated with the
antibodies overnight at room temperature followed by incubation
with appropriate secondary antibodies [31]. Upon completion of the
incubations, the specimens were counterstained with hematoxylin.
MouseIgGwasusedasanegativecontrol.Theslideswereexamined
under a light microscope for (a) the extent of integration, as
evidenced by the extent of organization of intact and nucleated fat
cells,(b)the extent offibrosis,asevidenced bythe amountofcollagen
and elastic fibrils, (c) the presence of cysts and vacuoles, and (d) the
intensity of the inflammatory response, as evidenced by the extent of
lymphocyte and macrophage infiltration. Each criterion was graded
on a scale of 0 to 5 where 0= absence, 1= minimal presence, 2=
minimal to moderate presence, 3= moderate presence, 4=
moderate to extensive presence, and 5= extensive presence.
Quantification of macrophage infiltration in the fat grafts was
estimated by counting the number of CD68-positive cells in five
fields per fat graft in all fat graft sections. Microvascular density
(MVD) in fat grafts was determined in five regions of interest
where the CD31 antibody signal was the most intense in each
section in all of the fat graft sections. The number of macrophages
and blood vessels in each region was counted under a light
microscope at 4006 magnification. The assessment in each fat
graft was made by calculating the mean result in two different
sections per fat graft and five different fields of view per section. All
evaluations were made by SH, DK, DE, and YU, who were blind
to the treatment of the mice.
Determination of the extent of apoptosis in the fat grafts
The extent of apoptosis in all fat grafts was assessed by the
terminal deoxyuridine triphosphate nick end labeling (TUNEL)
assay using a commercial kit (ApopTagH Plus Fluorescein Kit,
EPO Effect on Fat Grafts
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instructions. Duplicate determinations were done in each sample,
and were processed by fluorescence-activated cell sorting (FACS)
(Becton Dickinson, NJ, USA). Data were analyzed using the
Macintosh CELLQuest software program (Becton Dickinson).
In vitro tube formation of HUVECs on matrigel
The in vitro angiogenic potential of VEGF and EPO was
assessed by their ability to form tubes of endothelial cells on
matrigel. To this end, human umbilical vein endothelial cells
(HUVECs) were first cultured on fibronectin-coated 6-well plates
in endothelial basal medium-2 (EBM-2) (PromoCell, USA) and
then treated with 0, 20 or 100 IU/ml EPO for 48 hours before
their use in the assay. In a second experiment, HUVECs were
exposed to 0, 100 IU/ml EPO and 200 ng/ml VEGF for
48 hours in EBM-2 that contained or lacked 0.25 mg/ml
bevacizumab (AvastinH, Genentech, San Francisco, CA, USA), a
humanized monoclonal antibody that antagonizes the actions of
VEGF. After 48 hours, the untreated HUVECs, the VEGF- and
EPO-treated HUVECs, and the VEGF+bevacizumab- and
EPO+bevacizumab-treated HUVECs were detached gently by
0.5% trypsin/EDTA, and then suspended in EBM-2. At the same
time, frozen matrigel (Sigma Aldrich, St Louis MO, USA) was
thawed, and spread onto 96-well plates (40ml/well) at room
temperature for 30 minutes to allow solidification. The detached
untreated HUVECs, VEGF- and EPO-treated HUVECs, and
VEGF+bevacizumab- and EPO+bevacizumab-treated HUVECs
(5610
4 cells/150ml EBM-2/well) were placed on the matrigel
surface, and then incubated at 37uC for 24 hours in EBM-2. After
plating on the matrigel, the VEGF- and EPO-treated HUVECs
and VEGF+bevacizumab- and EPO+bevacizumab-treated HU-
VECs were treated a second time with identical concentrations of
EPO, VEGF, and bevacizumab, respectively. After 24 hours, the
non-integrated cells were removed by washing, and tube
formation on the matrigel was assessed under a light microscope
at 106 magnification. The tubular structures were graded
semiquantitatively by evaluating the presence and stages of tube
formation on a scale of 0 to 5: 0= well separated individual cells,
Figure 1. Photograph of five representative mice with fat grafts at the end of the 15-week study period. (A) Five PBS-treated fat grafts
with small lumps that vary in size in the scalps. (B) Five high-dose erythropoietin (100 IU EPO)-treated fat grafts with large lumps that are similar in
size in the scalps. (C) Fat grafts were dissected from the mice 15 weeks after transplantation. From left to right, a representative small fat graft froma
PBS-treated fat graft, an intermediate-size low-dose EPO-treated fat graft, and a large high-dose EPO-treated fat graft respectively. Scale bar: 10 mm.
doi:10.1371/journal.pone.0013986.g001
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capillary tubes and no sprouting, 3= visible sprouting of new
capillary tubes, 4= early formation of closed polygons, 5=
development of complex mesh-like structures. All evaluations were
assessed by SH, DE and DK, who were blind to the treatments.
Four random high-power fields in each sample were examined
from three independent experiments. The results from each
examiner were then pooled in order to calculate the mean value
for each criterion for each sample in each group.
HUVEC proliferation
To investigate EPO-induced angiogenesis through mechanisms
involving pro-angiogenic factors, we measured the proliferation of
EPO-treated HUVECs in the presence of various pro-angiogenic
factor inhibitors. To this end, HUVECs (2610
5 cells/well) were
cultured on fibronectin-coated 12-well plates in EBM-2. The
cultured HUVECs were treated with or without 100 IU/ml EPO
for 48 hours, and then exposed for 3 hours to (a) 0.25 mg/ml
bevacizumab, (b) 100 nM of PD173074; an inhibitor of bFGF
(Calbiochem, San Diego, CA), (c) 20 mM of tyrphostin AG 1296; a
selective inhibitor of PDGF (sigma), (d) a combination of
bevacizumab, PD173074 and tyrphostin, and to (e) 100 nM
wortmannin; a phosphatidylinositol 3-kinaz (PI 3-K) inhibitor
(sigma). Upon the completion of the experiment, the cells were
washed with PBS and then incubated with [
3H]-thymidine (NEN,
Boston, MA, USA) (1 mCi/ml medium) for 5 h at 37uC.
Thereafter, 0.5 ml cold 10% Trichloroacetic acid (TCA) was
added into each well for another 30 min at 4uC. To extract the
3H-thymidine labeled DNA, 0.5 ml 1N NaOH was added to each
well for 10 min at room temperature, and then 0.5 ml 1N HCl
was added and mixed well. Samples of mixture solution (0.5 ml)
was taken from each well and added to scintillation vials for the
measurement of [
3H]-thymidine incorporation to DNA (cpm/mg
protein). Duplicate cell counts were averaged for 3 experiments.
Data were expressed as the percentage of control.
Western analysis
The expression levels of the angiogenic factors, bFGF, IGF-1,
PDGF-BB, VEGFR-2, EPOR and MMP-2, the cell survival factor
PKB and phosphorylated PKB, and the pro-apoptotic factors
caspase 3 and cytochrome c weredeterminedin homogenates of the
harvested fat grafts using western blot analysis. Homogenates of
samples from the fat grafts were lysed in RIPA buffer (R&D
Systems). A 40-mg aliquot of each lysate was loaded onto SDS-
PAGE, and then transferred to nitrocellulose membranes. Mem-
branes were then incubated with monoclonal antibodies against
bFGF, IGF-1, PDGF-BB, MMP-2, PKB, phosphoPKB, caspase 3,
and cytochrome c (all purchased from Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and with monoclonal antibodies against
VEGFR-2 and EPOR (R&D systems), followed by a second
incubation with a horseradish peroxidase (HRP)-conjugated IgG
secondary antibody (Santa Cruz Biotechnology). An antibody
against b-actin (Santa Cruz) was used to normalize protein loading.
The resultant bands were quantified by densitometry.
Statistical analysis of the data
The data for each study parameter from the PBS-, the VEGF-
and the EPO-treated fat grafts in each treatment group were
pooled, and the results are presented as mean 6 standard deviation
(SD). The data have a normal distribution by the Kolmogorov-
Smirnov test. The data from the first experiment were analyzed by
ANOVA and the data from the second experiment were analyzed
by Student’st test,using a computerized statisticalsoftware program
(Prism version 5.0, GraphPad Software Inc, CA, USA). Differences
were considered statistically significant when P#0.05. Kappa values
for intra-examiner repeatability of the blinded evaluations of
histological analysis, MVD, and tube formation on matrigel were
0.94, 0.89, and 0.93, respectively.
Results
All mice in all of the treatment groups of both experiments
completed the 15-week study period. They appeared to be healthy
and there was no evidence of cachexia during the entire study
period. There were no significant changes in red blood cell,
leukocyte, and platelet counts, and in plasma hemoglobin and
EPO concentrations in the mice that had either PBS-treated- or
low-dose EPO-treated fat grafts (Table 1). The red blood cell,
leukocyte platelet counts, and plasma EPO concentrations, but not
the plasma hemoglobin concentrations, were significantly in-
creased in the mice with high-dose EPO-treated fat grafts (Table 1).
Eighteen days after transplantation, plasma VEGF concentrations
were significantly increased in both groups of mice with EPO-
treated fat grafts. At the end of the 15-week study period, the
plasma VEGF concentrations in the two groups of mice with
EPO-treated grafts were not significantly different from baseline
values, or from those in mice with PBS-treated fat grafts. EPO
concentrations in the PBS- and EPO-treated grafts were not
different from each other at each of the three time points (Table 1).
Fat graft weights and volumes
A well-defined subcutaneous lump was observed on the scalp of
each mouse at the end of the 15-week study period (Figure 1). The
weights and volumes of the EPO-treated grafts were higher than
those of the PBS-treated grafts (Table 2). The weights and volumes
of the PBS-treated fat grafts in the first experiment were not
different from those of the PBS- and VEGF-treated grafts in the
second experiment (Table 2).
Histological evaluation
The histological criteria of the PBS-treated fat grafts in the first
experiment were not different from those in the second experiment.
The extent of integration of the fat graft was higher in the high-dose
EPO-treated grafts than in the low-dose EPO- and PBS-treated
grafts (Figure 2A), and, the extent of cyst formation and fibrosis was
lower in the high-dose EPO-treated grafts than in the low-dose
EPO- and PBS-treated grafts (Table 3). The extent of integration,
cyst formation, and fibrosis in the VEGF-treated grafts were not
different from those in the PBS-treated grafts (Table 3).
The effect of EPO on inflammatory response and MVD in
the fat grafts
The severity of the inflammatory response as evidenced by CD68-
positive cells infiltration in fat gr a f t sb o t hi nt h el o w - d o s ea n di nt h e
high-dose EPO-treated fat grafts was lower than the severity of the
inflammatory response in the PBS-treated fat grafts. The severity of
the inflammatory response in the high-dose EPO-treated grafts was
significantly lower than that observed in the low-dose EPO-treated
grafts (Figure 2B and 2D left). However, the intensity of the
inflammatory response in the VEGF-treated fat grafts was signifi-
cantlyhigherthanthatobservedinthePBS-treatedfatgrafts(Table3).
The MVDs observed in both the high-dose and low-dose EPO-
treated fat grafts were significantly higher than the MVDs of the
PBS-treated fat grafts, and the effect of EPO on MVD was dose-
dependent. Avascular areas, ectatic vessels with edema and
perivascular hemorrhage, and a marked reduction in capillary
ramification were observed in the PBS-treated fat grafts. In the
EPO-treated fat grafts, there were well-vascularized areas with
EPO Effect on Fat Grafts
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(Figure 2C and 2D middle). The extent of MVD was negatively
correlated to the extent of macrophage infiltration in the fat grafts
(Figure 2D right).
The effect of EPO on VEGF content and expression levels
of angiogenic factors and PKB in the fat grafts
The VEGF contents in the low-dose and high-dose EPO-treated
fat grafts were significantly higher than the VEGF contents in the
PBS-treated fat grafts. The VEGF content in the high-dose EPO-
treated grafts was significantly higher than that observed in the
low-dose EPO-treated graft (Figure 3A upper panel and 3C left).
EPO induced a dose-dependent increase in the expression levels of
bFGF, IGF-1, PDGF-BB, MMP-2, PKB, and phosphoPKB
(Figure 3B). Furthermore, EPO increased both tissue VEGFR-2
and EPOR expression in a dose-dependent manner, as evidenced
by immunohistochemical localization of both factors (Figure 3A
middle and lower panels respectively) and by western blot analysis
(Figure 3C middle and left respectively). The VEGF content and
the mean expression levels of both VEGFR-2 and EPOR were
positively correlated with MVD (Figure 3D).
The effect of EPO on the extent of apoptosis in the fat
grafts
The extent of apoptosis in the PBS-treated fat grafts was greater
than that in the low-dose and high-dose EPO-treated fat grafts.
The extent of apoptosis in the high-dose EPO-treated fat grafts
was significantly lower than that in the low-dose EPO-treated graft
(Figure 4A). EPO caused a dose-dependent decrease in the
expression levels of caspase 3 and cytochrome c (Figure 4B).
The effect of VEGF on MVD and extent of apoptosis in
the fat grafts
The extent of apoptosis and the MVD observed in the PBS-
treated fat grafts were the same in both the first and the second
Table 1. Effect of EPO treatment on body weight, hematology, and plasma and tissue EPO concentrations in the three
experimental groups.
Group Control (n=10) Low-dose EPO (n=10) High-dose EPO (n=10)
Initial mice weight (g) 26.761.1 25.961.1 26.261.0
After EPO treatment 27.361.1 27.961.1 28.661.2
At week 15 28.361.1 28.861.1 29.061.2
Initial RBC count (10
6/mm
3) 7.860.9 8.061.0 7.961.2
After EPO treatment 7.960.9 8.061.1 8.961.0*
At week 15 7.860.9 7.961.0 8.161.2
Initial leukocyte count (10
6/mm
3) 10.861.2 11.161.1 10.961.2
After EPO treatment 11.261.2 11.461.1 13.161.3*
At week 15 11.061.1 10.861.1 11.461.2
Initial platelet count (10
3/L) 593654 609663 603672
After EPO treatment 579658 621668 741681**
At week 15 593654 601657 597664
Initial hemoglobin conc. (g/dl) 14.461.3 15.161.4 15.561.4
After EPO treatment 14.861.3 15.761.4 16.461.6
At week 15 14.861.2 15.161.6 14.961.5
Initial plasma EPO conc. (mU/mL) 14.361.9 14.661.3 14.261.7
After EPO treatment 13.761.4 17.663.3* 46.768.7***
At week 15 14.361.7 14.261.3 14.161.3
Initial plasma VEGF conc. (pg/mL) 38.663.9 34.864.6 39.264.8
After EPO treatment 37.163.8 51.566.6* 8769.2***
At week 15 38.063.3 36.664.9 37.465.3
Tissue EPO conc. (mU/mL) 0.360.1 0.360.1 0.360.1
Footnotes
Values are presented as mean 6 SD; n = number of mice; conc. = concentrations; RBC = red blood cells; EPO = erythropoietin; VEGF = vascular endothelial growth
factor. *P,0.05, **P,0.01, ***P,0.001 for the difference between either the low-dose- or the high-dose-treated EPO grafts and the PBS-treated grafts.
doi:10.1371/journal.pone.0013986.t001
Table 2. Effect of EPO treatment on fat graft weight and
volume in all treatment groups in the two experiments.
First experiment Second experiment
Group
PBS
(n=10)
Low-dose
EPO
(n=10)
High-dose
EPO
(n=10)
PBS
(n=10)
VEGF
(n=10)
Weight (g) 0.360.1 0.560.2** 0.660.2*** 0.3260.2 0.3560.2
Volume (ml) 0.360.1 0.460.1** 0.660.1*** 0.3560.1 0.3660.2
Footnotes
Values are presented as mean 6 SD.
n = number of mice.
EPO = erythropoietin.
VEGF = vascular endothelial growth factor.
**P,0.01, ***P,0.001, for the difference between either the low-dose- or the
high-dose EPO-treated fat grafts and the PBS-treated grafts.
doi:10.1371/journal.pone.0013986.t002
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e13986Figure 2. Histological sections of fat grafts that were removed from the PBS-treated, low-dose, and high-dose EPO treated mice 15
week after fat transplantation. The fat grafts from three different groups of mice were treated with either PBS (100 ml), 20 IU EPO/100 ml PBS (low-
dose), or 100 IU EPO/100 ml PBS (high-dose) on the day of the fat injection, and the treatments were repeated every three days for 18 days. After
harvesting, sections were stained with hematoxylin and eosin or prepared for assessing inflammatory cell infiltration and MVD, and then examined
under a light microscope for (a) the extent of integration, as evidenced by the extent of organization of intact and nucleated fat cells in the grafted fat
tissue architecture, (b) the extent of fibrosis, as evidenced by the amount of collagen and elastic fibrils, (c) the presence of cysts and vacuoles, (d) the
intensity of the inflammatory response, as evidenced by the extent of macrophage infiltration, and (e) MVD, as evidenced by the number of blood
vessels in the fat grafts. Representative histological micrographs of PBS-, and low-dose- and high-dose-EPO treated fat grafts (left to right). (A) fat cell
integration in fat grafts, (B) inflammation as evidenced by infiltration of CD68-positive cells (macrophages) in fat grafts, and (C) vascularization in the
fat grafts as evidenced by MVD which was quantified by counting CD31-positive vessels. The arrows are pointing to dark-stained CD68-positive
macrophages and to red-stained CD31-positive endothelial cells. (D) EPO treatment decreases inflammation (left) and increases MVD (middle) in a
dose-dependent manner that correlates negatively (right). Each bar represents the mean CD68-positive cells or MVD 6 SD from five regions of
interest in each fat graft from each treatment group at the end of the 15-week study period. *P,0.05, ***P,0.001, for the difference between either
the low-dose- or the high-dose EPO-treated fat grafts and the PBS-treated grafts. Scale bar for A: 200mm, scale bar for B or C: 400mm.
doi:10.1371/journal.pone.0013986.g002
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treated fat grafts were higher than, but not statistically different
from, those in the PBS-treated fat grafts (Figures 5A and 5B).
There was unorganized vessel formation and perivascular
hemorrhage in the VEGF-treated fat grafts. The extent of
apoptosis in the VEGF-treated fat grafts was greater than that
observed in the PBS-treated fat grafts (Figure 5C). There were no
statistical differences in the expression levels of caspase 3 and
cytochrome c in the PBS-treated and in the VEGF-treated fat
grafts (Figure 5D).
The effect of EPO on endothelial cell proliferation and
tube formation on matrigel
VEGF significantly increased HUVEC tube formation and
EPO increased HUVEC tube formation in a dose-dependent
manner (Figure 6A). Tube formation was substantially reduced in
VEGF + bevacizumab-treated HUVECs, but not in the EPO +
bevacizumab-treated HUVECs (Figures 6B and 6C). The VEGF
inhibitor, bFGF inhibitor and PDGF inhibitor each reduced
HUVEC proliferation significantly, whereas either a combination
of the 3 inhibitors together or wortmannin alone abolished
HUVEC proliferation. EPO normalized HUVEC proliferation in
the presence of any of the inhibitors, but had no effect on HUVEC
proliferation in the presence of a combination of the 3 inhibitors
together or in the presence of wortmannin alone (Figure 6D).
Discussion
The main finding of our study is that the decrease in the weight
and volume of EPO-treated human fat grafts was smaller than the
decrease that was observed in VEGF- and PBS-treated human fat
grafts in immunologically-compromised nude mice. Treatment of
the fat grafts with EPO (a) increased the expression levels of
various angiogenic factors, induced the expression of cell survival
factors such as PKB, and increased the extent of MVD, (b)
increased fat cell survival and (c) reduced the extent of
inflammatory response and fat cell apoptosis in a dose-dependent
manner. The histological assessments of the harvested fat grafts
showed that EPO treatment led to better fat tissue integration with
less cysts, fibrosis, and inflammatory cell infiltration compared to
the PBS- and VEGF-treated fat grafts. From these results, we
concluded that treatment of fat grafts with EPO improves the fat
graft’s integration into the surrounding tissues and its long-term
survival following fat transplantation. Our data suggests that EPO-
induced angiogenesis in the transplanted graft occurs due to
stimulation of a cluster of angiogenic factors that include VEGF,
bFGF, PDGF-BB, MMP-2, and IGF-1 that has been shown to
increase the survival of grafted fat cells [32]. These findings are in
agreement with those of Pallua and colleagues, who reported that
VEGF, bFGF, PDGF-BB, and IGF-1 are all required for
promoting fat cell viability and adipogenesis [33].
Vascularization is essential for graft survival. After autologous
fat transplantation, the increased resorption and the inability of a
fat graft to survive in the recipient is associated with reduced fat
tissue vascularization, and increased apoptosis of fat cells in the
graft [20,21,22]. VEGF is a known potent angiogenic factor that
influences endothelial proliferation, migration and viability and
induces angiogenesis of adipose tissue after transplantation
[34].VEGF gene therapy in fat grafts can induce angiogenesis
and enhance fat cell survival and viability [21]. Recently, Lu and
colleagues demonstrated in an elegant study, that modified
adipose-derived stem cells that overexpressed VEGF can enhance
the survival and quality of transplanted fat tissue through an
angiogenesis-dependent mechanism [26]. In our study, we
demonstrated that exogenous VEGF treatment of fat grafts has
no effect on their weight and volume compared to the same
parameters in PBS-treated fat grafts. We also observed that the
MVD of the VEGF-treated fat grafts was modestly higher than
that of the PBS-treated fat grafts. In addition, we found that the
extent of apoptosis in these VEGF-treated fat grafts was not
different from that in the PBS-treated fat grafts, and this could
probably indicate that VEGF does not exert an anti-apoptotic
effect in the fat grafts. The process of angiogenesis involves a
harmonized interplay between various angiogenic factors that
include growth factors such as bFGF, VEGF, PDGF-BB, and
proteases such as MMPs that digest constituents of the
extracellular matrix that impede angiogenesis. These factors act
synergistically in order to improve the survival of adipose tissue
after fat transplantation [23,24]. Therefore, the therapeutic use of
one of these angiogenic factors, even one as potent as VEGF, may
not be sufficient to promote angiogenesis for enhancing fat tissue
viability and survival. Contrary to the findings of Yi [21], Lei [25],
Lu [26] and their colleagues who found that either gene therapy
with VEGF, or adipose derived-stem cell therapy that overex-
pressed VEGF, can enhance fat cell viability and survival, we are
of the opinion that the angiogenic actions of exogenous VEGF
may not be adequate to elicit an appropriate angiogenic response
in transplanted fat tissue. Indeed, the increased VEGFR-2
expression in the EPO-treated fat grafts that was observed in
our study implies that EPO-induced endogenous VEGF secretion
in the fat grafts might be more effective than exogenous VEGF
administration.
Nakano and colleagues demonstrated that EPO treatment
increases VEGF expression and promotes angiogenesis in
peripheral ischemic tissues in mice [10]. We recently reported
that topical EPO treatment induces VEGF secretion and
angiogenesis in excisional wounds in diabetic rats [35]. In the
current study, we showed that treatment of fat grafts with EPO
increased VEGF, bFGF, IGF-1, PDGF-BB and MMP-2 contents,
as well as MVD in the fat grafts. We also observed that, similarly
to VEGF, EPO increased HUVEC tube formation on matrigel,
thereby confirming that EPO has angiogenic activity. Interesting-
ly, bevacizumab abolished VEGF-induced tube formation, but not
EPO-induced tube formation. This result suggests that the
angiogenic activity of EPO on HUVECs is indirect, and could
be mediated by stimulating other growth factors, such as bFGF
Table 3. Histological analysis of the dissected fat grafts in all
treatment groups in the two experiments.
First experiment Second experiment
Group
PBS
(n=10)
Low-dose
EPO
(n=10)
High-dose
EPO
(n=10)
PBS
(n=10)
VEGF
(n=10)
Integration 3.361.0 4.360.8 4.660.7* 3.660.7 3.260.9
Fibrosis 2.560.9 2.160.6 1.560.7* 2.660.5 2.960.7
Cyst/Vacuoles 2.860.9 2.060.9 1.760.7* 2.961.0 3.361.0
Inflammation 2.961.1 1.760.5* 1.360.6** 3.2.061.4 4.061.2*
Footnotes
Values are presented as mean 6 SD.
n = number of mice.
EPO = erythropoietin.
VEGF = vascular endothelial growth factor.
*P,0.05, **P,0.01 for the difference between either the low-dose- or the high-
dose EPO-treated fat grafts and the PBS-treated grafts.
doi:10.1371/journal.pone.0013986.t003
EPO Effect on Fat Grafts
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13986and PDGF-BB, and proteases such MMP-2. Furthermore, EPO
normalized in vitro HUVEC proliferation in the presence of a
single growth factor inhibitor such as bevacizumab (VEGF
inhibitor), PD173074 (bFGF inhibitor) or tyrphostin (PDGF
inhibitor), strengthening our claim that the use of one growth
factor for fat tissue vascularization might not be adequate. On the
other hand, EPO has no effect on the proliferation of HUVECs
that were exposed to the above mentioned inhibitors simulta-
Figure 3. Effect of EPO on the expression levels of angiogenic growth factors in the fat grafts. The fat grafts from the three different
groups of mice were treated with either PBS (100 ml), 20 IU EPO/100 ml PBS (low-dose), or 100 IU EPO/100 ml PBS (high-dose) on the day of the fat
injection, and the treatments were repeated every three days for 18 days. (A) Representative histological micrographs of PBS-, and low-dose- and
high-dose-EPO treated fat grafts (left to right) presenting VEGF expression (upper panel), VEGFR-2 expression (middle panel), and EPOR expression
(lower panel). (B) Representative western blots of the expression levels of the angiogenic factors in the PBS- and EPO-treated fat grafts at the end of
the 15-week study period. bFGF: basic fibroblast growth factor; IGF-1: insulin-like growth factor-1; PDGF-BB: platelet-derived growth factor-BB; MMP-
2: matrix metalloproteinase-2; PKB: protein kinase B; phosphoPKB: phosphorylated PKB. (C) Graphs representing the mean VEGF content (left), the
mean VEGFR-2 expression (middle) and the mean EPOR expression (right) 6 SD in the fat grafts in each treatment group. (D) The correlation between
VEGF and MVD (left), and between mean VEGFR-2 (middle) and EPOR (right) expression and mean MVD in each group. *P,0.05, **P,0.01,
***P,0.001for the difference between either the low-dose- or the high-dose EPO-treated fat grafts and the PBS-treated grafts. Scale bar: 200mm.
doi:10.1371/journal.pone.0013986.g003
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13986Figure 4. Effect of EPO on the extent of apoptosis in the fat grafts. PBS (100 ml), 20 IU EPO/100 ml PBS (low-dose), or 100 IU EPO/100 mlP B S
(high-dose) were injected into fat grafts in three different groups of mice on the day of the fat injection and then repeated every three days for 18 days.
(A) The extent of apoptosis was measured by the TUNEL assay, and is expressed as a percentage of the presence of apoptosis in the PBS-treated fat grafts.
Eachbarrepresents the mean extentofapoptosis 6SD inthefatgraft ineachtreatmentgroupat theendofthe15-week study period.*P,0.05,**P,0.01,
***P,0.001 for the difference between either the low-dose- or the high-dose EPO-treated fat grafts and the PBS-treated grafts. (B) Representative western
blots of the expression levels of caspase 3 (Casp 3) and cytochrome c (Cyt c) in the PBS- and EPO-treated fat grafts at the end of the 15-week study period.
doi:10.1371/journal.pone.0013986.g004
Figure 5. Effect of VEGF on MVD and the extent of apoptosis in the fat grafts. PBS (100 ml) or VEGF (200 ng VEGF/100 ml PBS) were injected
into the fat grafts in two different groups of mice on the day of the fat injection and every three days for 18 days. (A) Each bar represents the mean
MVD 6 SD from five regions of interest in each slide that was prepared from the harvested fat grafts of each treatment group at the end of the 15-
week study period. (B) Each bar represents the mean VEGF content 6 SD in the harvested fat grafts in each treatment group at the end of the 15-
week study period. (C) The extent of apoptosis was measured by the TUNEL assay, and is expressed as a percentage of the extent of apoptosis in the
PBS-treated fat grafts. Each bar represents the mean extent of apoptosis 6 SD in the fat graft in each treatment group at the end of the 15-week
study period. **P,0.01for the difference between the VEGF-treated fat grafts and the PBS-treated grafts. (D) Representative western blots of the
expression levels of caspase 3 (Casp 3) and cytochrome c (Cyt c) in the PBS- and VEGF-treated fat grafts at the end of the 15-week study period.
doi:10.1371/journal.pone.0013986.g005
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PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e13986neously, supporting the idea that secretion of a cluster of growth
factors accounts, at least, to one of the underlying mechanisms of
EPO action on fat graft vascularization. In addition, EPO
increased PKB expression and activity in the fat grafts, and PKB
is critical for the cellular pathway of a broad spectrum of growth
factors. Nevertheless, EPO has no effect on the proliferation of
HUVECs that were exposed to wortmannin which inhibits the
phosphorylation of phosphatidylinositol 3-kinases (PI 3-K) and
subsequently the phosphorylation of PKB, confirming that EPO
stimulates the secretion of multiple growth factors, at least
partially, through the PI 3-K/PKB cellular pathway. In light of
our results, we attribute the beneficial effects of EPO on the
improved viability of fat grafts, partly, to this action on
angiogenesis in the fat grafts.
Nishimura and colleagues reported that the sustained volume
loss of fat grafts, even in those that are vascularized, is due to fat
cell apoptosis [22]. We observed that the inflammatory response in
the PBS-treated fat grafts was greater than the inflammatory
response in the EPO-treated fat grafts. This increased inflamma-
tion can be attributed to leukocyte and macrophage infiltration,
and to increased cytokine secretion in the fat graft. We found that
the extent of apoptosis in the EPO-treated fat grafts decreased in a
dose-dependent manner. These findings are not surprising since
EPO has well-known anti-apoptotic properties, and is an anti-
inflammatory cytokine [15]. Accordingly, we concluded that EPO
decreases the rate of fat resorption by directly decreasing the
extent of apoptosis in fat cells and/or indirectly by suppressing the
inflammatory response that ensues after fat grafting.
Aspirated fat tissue that is used for autologous fat transplanta-
tion is devoid of blood microvessels because these microvessels are
destroyed during the aspiration, and removed during processing
prior to its injection. Therefore, the fat tissue that is injected into a
recipient is considered to be an ischemic fat cell mass. During the
early period following transplantation, the fat transplant exists
under hypoxic and hyponutritional conditions. Should revascu-
larization fail to be initiated in this early period, apoptosis ensues
and results in late fat cell degeneration and fat resorption [22]. In
this study, we provoked angiogenesis at the time of fat injection,
and for the 18 days after transplantation, by repeated injections of
EPO into the fat graft. By doing this, we hoped to induce
angiogenesis in the transplanted fat tissue while it is still an
ischemic cell mass, in order to promote fat cell survival by
increasing the delivery of oxygen and nutrients. At the same time,
we thought that this treatment would protect the transplanted fat
cell mass from early degeneration, and delay and/or prevent fat
cell apoptosis. As already noted, EPO exerts an anti-apoptotic
action on fat cells because EPO decreases the extent of DNA
fragmentation, caspase-3 activity and cytochrome c in the fat
grafts. This anti-apoptotic action might be obtained due to a direct
effect of EPO on fat cell apoptosis, and/or an indirect effect by
promoting fat graft vascularization. Nevertheless, treatment of the
fat grafts with exogenous VEGF did not alter the extent of
apoptosis in the fat grafts, although it had modestly increased the
vascularization in the fat grafts compared to control fat grafts.
The overall clinical experience on the use of growth factors and
cytokines to reduce the rate of fat resorption by increasing fat graft
vascularization has not been encouraging [21,36,37]. We found
that fat graft treatment by EPO improves the survival of a human
fat graft in nude mice since EPO not only increased angiogenesis,
but also reduced the inflammatory response and fat cell apoptosis.
EPO can account for some use-limiting adverse effects, as it may
promote hypertension, retinopathy, neurotoxicity and thrombotic
events when it is used in the repetitive and large doses that are
required for adequate tissue protection. It may also lead to an
increased risk of spread of tumor growth due to its effect on
angiogenesis, as has been observed particularly in patients with
chronic diseases and in patients with cancer [38]. Nevertheless,
EPO has been safely used in humans for many years for treating
anemia, and in trials that tested EPO as a neuroprotective/
neuroregenerative agent [39]. The production of EPO by means
of recombinant techniques and its availability in various
competent recombinant forms, make EPO an economical drug,
conferring it as a potential candidate for enhancing fat
transplantation without increasing considerably the cost of the
procedure.
In conclusion, the failure of exogenous VEGF to stimulate
adequate angiogenesis and to prevent apoptosis in fat grafts
strengthens our hypothesis that fat cell survival and viability
depend on the action of a cluster of angiogenic factors as well as on
prevention of fat cell apoptosis, a process which can be improved
by promoting them. We found that EPO treatment of transplanted
fat acts through these two mechanisms, and can improve fat graft
integration and its long-term survival in immunologically-com-
promised nude mice. Based on our results, we propose that EPO
treatment can significantly improve the efficacy of human
autologous fat transplantation for soft tissue filling and augmen-
tation. To the best of our knowledge, the results of this study are
the first to demonstrate the effect of EPO on fat resorption.
Further studies in animals and humans are now needed in order to
validate our data.
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Figure 6. Effect of EPO on HUVEC proliferation and tube formation on matrigel. HUVECs were treated with either 20 IU/ml or 100 IU/ml
and either 100 IU/ml EPO or 200 ng/ 100ml VEGF in the absence or presence of 0.25 mg/ml bevacizumab for 48 hours after plating the cells on
matrigel. The extent of HUVEC tube formation on matrigel was assessed after 24 hours under a light microscope at 106magnification. The tubular
structures were graded semiquantitatively on a scale of 0 to 5 by evaluation of the relative presence and stages of formation of tubes on the matrigel:
0= well separated individual cells, 1= cells had begun to migrate and align themselves, 2= visible capillary tubes and no sprouting, 3= visible
sprouting of new capillary tubes, 4= early formation of closed polygons, 5= development of complex mesh-like structures. (A) Each bar represents
the mean grade of tube formation 6 SD in the matrigel. *P,0.05, **P,0.01 and ***P,0.001. (B) The white bars are the mean grade of tube formation
6 SD in the matrigel of untreated HUVECs, VEGF- and EPO-treated HUVECs. The black bars represent the mean grade of tube formation 6 SD in the
matrigel of untreated HUVECs VEGF- and EPO-treated HUVECs that were exposed to bevacizumab. *P,0.05 and ***P,0.001, for the difference
between HUVECs that were or were not exposed to bevacizumab. NS = not significantly different. (C) From top to bottom: representative
micrograph of untreated HUVECs on matrigel, VEGF- and EPO-treated HUVECs after 24 hours of plating with (+) or without (2) bevacizumab.
(D) Cultured HUVECs were treated with or without 100 IU/ml EPO in the presence of either bevacizumab, PD173074, or tyrphostin, a combination of
bevacizumab, PD173074 and tyrphostin, or in the presence of wortmannin. Proliferation of HUVECs was measured by incorporation of [
3H]-thymidine
to DNA. Duplicate cell counts were averaged for 3 experiments and the data were expressed as the percentage of control. *P,0.05, **P,0.01 and
***P,0.001 for the difference between untreated, or EPO- treated HUVECs that were exposed to bevacizumab, PD173074, tyrphostin or wortmannin.
NS = not significantly different.
doi:10.1371/journal.pone.0013986.g006
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